SCLX Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Scilex Holding Company (NASDAQ: SCLX)
›
Scilex Holding Company (NASDAQ: SCLX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 0.5658 USD on 20 November 2026, down 94.6% over 52 weeks. Its 52-week range is 0.5000 USD to 16.81 USD: the price is 96.6% below the high and 13.2% above the low.
Its market capitalisation is 3.98M USD.
Scilex Holding Company reports return on equity of 172.6% and revenue down 22.8% year over year.
Its debt exceeds its cash by 105.40M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.